Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment

Trial Profile

A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Tavokinogene telsaplasmid (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-695; PISCES
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 12 Dec 2018 According to an OncoSec Medical media release, Adil Daud, MD, HS Clinical Professor, Department of Medicine (Hematology/Oncology), is a Lead Principle Investigator of this study.
    • 12 Dec 2018 According to an OncoSec Medical media release, enrollment is ongoing and the Company expects to complete the study next year.
    • 12 Dec 2018 According to an OncoSec Medical media release, results (n=9) were presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting (SITC) in Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top